AMAG Pharmaceuticals, Inc. Announces Issuance Of New U.S. Patent For Ferumoxytol

Published: Jan 31, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass., Jan. 31, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to AMAG for ferumoxytol, U.S. Patent No. 8,591,864, Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents, expiring in March 2020. This patent is directed to compositions that include the chemical structure and to 500 mg to 600 mg unit doses of ferumoxytol. This patent is listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the United States Food and Drug Administration.

Help employers find you! Check out all the jobs and post your resume.

Back to news